Table 1.
Epigenetic Mechanisms | Change in SLE | Outcomes | References |
---|---|---|---|
DNA methylation | Hypomethylation of CD40L promotor in CD40+ T cells | Association with clinical disease activity | Vordenbäumen et al., 2021 [17] |
Hypomethylation of IL-10 and IL-13 gene regulatory domains | Overexpression of IL-10 and IL-13 | Zhao et al., 2010 [18] | |
ncRNAs | Overexpression of miR-29b | Reduction of DNMT1 levels, DNA hypomethylation, and upregulation of genes encoding CD11 and CD70 | Qin et al., 2013 [19] |
Overexpression of miR-126 in CD4+ T cells | Contribution to T cell autoreactivity by targeting DNMT1 | Zhao et al., 2011 [20] | |
Reduced expression of miR-142-3p/5p in CD4+ T cells | T cell hyperactivity and B cell hyperstimulation | Ding et al., 2020 [21] | |
Histone modifications | Elevated histone H3 acetylation in CD4+ T cells | Correlation with clinical disease activity | Zhou et al., 2011 [22] |
High methylation in the HDAC6 promoter | Lower HDAC6 levels and SLE susceptibility | Fang et al., 2016 [23] |
SLE: systemic lupus erythematosus; DNMT1: DNA methyltransferase 1; HDAC6: histone deacetylases 6.